Rational design of HIV vaccines and microbicides: Report of the EUROPRISE network annual conference 2010

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Brinckmann, Sarah ^a   da Costa, Kelly ^b   van Gils, Marit J ^c   Hallengärd, David ^d   Klein, Katja ^b   Madeira, Luisa ^b   Mainetti, Lara ^e,f   Palma, Paolo ^g   Raue, Katharina ^h   Reinhart, David ⁱ   Reudelsterz, Marc ^j   Ruffin, Nicolas ^d   Seifried, Janna ^j   Schäfer, Katrein ^k   Sheik Khalil, Enas ^l   Sköld, Annette ^m   Uchtenhagen, Hannes ^m   Vabret, Nicolas ⁿ   Ziglio, Serena ^o   Scarlatti, Gabriella ^e   Shattock, Robin ^b   Wahren, Britta ^d   Gotch, Frances ^p   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d KAROLINSKA INSTITUTE   (Sweden)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^h GERMAN PRIMATE CENTER   (Germany)

ⁱ POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH   (Austria)

^j ROBERT KOCH INSTITUTE   (Germany)

^k UNIVERSITY OF YORK   (United Kingdom)

^l LUND UNIVERSITY   (Sweden)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ INSTITUT PASTEUR   (France)

^o UNIVERSITY OF VERONA   (Italy)

^p IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,6 O DIMETHYL BETA CYCLODEXTRIN; AZURIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHITOSAN; CYANOVIRIN N; DNA VACCINE; DOXYCYCLINE; ENFUVIRTIDE; HEAT SHOCK PROTEIN 70; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE; POLYETHYLENEIMINE DERIVATIVE; PROTEIN P27; RECOMBINANT GLYCOPROTEIN GP 120; RECOMBINANT VACCINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TETANUS TOXOID; TIFUVIRTIDE; ANTIINFECTIVE AGENT;

AFRICA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CD4+ T LYMPHOCYTE; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG INHIBITION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION; ANIMAL; ANTIBODY PRODUCTION; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DRUG DESIGN; IMMUNOLOGY;

AIDS VACCINES; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBODY FORMATION; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS;

EID: 79953869416     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-40     Document Type: Review

References (49)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220. 10.1056/NEJMoa0908492, 19843557.
2. Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, Robb M, Cox J, Vancott T, Marovich M, Stout R, et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008, 198:1482-1490. 10.1086/592507, 18808335.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174. 10.1126/science.1193748, 20643915.
4. Stone A. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov 2002, 1:977-985. 10.1038/nrd959, 12461519.
5. Chaudhari A, Fialho AM, Ratner D, Gupta P, Hong CS, Kahali S, Yamada T, Haldar K, Murphy S, Cho W, et al. Azurin, Plasmodium falciparum malaria and HIV/AIDS: inhibition of parasitic and viral growth by Azurin. Cell Cycle 2006, 5:1642-1648. 10.4161/cc.5.15.2992, 16861897.
6. Bewley CA, Kiyonaka S, Hamachi I. Site-specific discrimination by cyanovirin-N for alpha-linked trisaccharides comprising the three arms of Man(8) and Man(9). J Mol Biol 2002, 322:881-889. 10.1016/S0022-2836(02)00842-2, 12270721.
7. Sexton A, Drake PM, Mahmood N, Harman SJ, Shattock RJ, Ma JK. Transgenic plant production of Cyanovirin-N, an HIV microbicide. FASEB J 2006, 20:356-358.
8. The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nat Med 2010, 16:981-989. 10.1038/nm0910-981, 20823883.
9. Borrow P, Shattock RJ, Vyakarnam A. Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology 2010, 7:84. 10.1186/1742-4690-7-84, 2964587, 20937128.
10. Brave A, Hallengard D, Malm M, Blazevic V, Rollman E, Stanescu I, Krohn K. Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responses. Vaccine 2009, 27:184-186. 10.1016/j.vaccine.2009.04.013, 18992294.
11. Palma P, Romiti ML, Li Pira G, Montesano C, Mora N, Aquilani A, Santilli V, Tchidjou HK, Ivaldi F, Giovannelli L, et al. The PEDVAC trial: Preliminary data from the first therapeutic DNA vaccination in HIV-infected children. Vaccine 2011,
12. Shedlock DJ, Silvestri G, Weiner DB. Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol 2009, 9:717-728. 10.1038/nri2636, 19859066.
13. Jespers V, Harandi AM, Hinkula J, Medaglini D, Le Grand R, Stahl-Hennig C, Bogers W, El Habib R, Wegmann F, Fraser C, et al. Assessment of mucosal immunity to HIV-1. Expert Rev Vaccines 2010, 9:381-394. 10.1586/erv.10.21, 20370549.
14. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258:1938-1941. 10.1126/science.1470917, 1470917.
15. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, McDermott AB, Schultz A, Zamb TJ, Boyle R, Desrosiers RC. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006, 7:19-23. 10.1038/ni1296, 16357854.
16. Cranage MP, Whatmore AM, Sharpe SA, Cook N, Polyanskaya N, Leech S, Smith JD, Rud EW, Dennis MJ, Hall GA. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 1997, 229:143-154. 10.1006/viro.1996.8419, 9123856.
17. Genesca M, McChesney MB, Miller CJ. Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J Intern Med 2009, 265:67-77. 10.1111/j.1365-2796.2008.02051.x, 19093961.
18. Tenner-Racz K, Stahl Hennig C, Uberla K, Stoiber H, Ignatius R, Heeney J, Steinman RM, Racz P. Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. Proc Natl Acad Sci USA 2004, 101:3017-3022. 10.1073/pnas.0308677101, 365737, 14970317.
19. Sharpe SA, Whatmore AM, Hall GA, Cranage MP. Macaques infected with attenuated simian immunodeficiency virus resist superinfection with virulence-revertant virus. J Gen Virol 1997, 78(Pt 8):1923-1927.
20. Das AT, Klaver B, Centlivre M, Harwig A, Ooms M, Page M, Almond N, Yuan F, Piatak M, Lifson JD, Berkhout B. Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution. Retrovirology 2008, 5:44. 2443169, 18533993.
21. Das AT, Klaver B, Harwig A, Vink M, Ooms M, Centlivre M, Berkhout B. Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication. J Virol 2007, 81:11159-11169. 10.1128/JVI.01354-07, 2045552, 17670816.
22. Schultheiss T, Stolte-Leeb N, Sopper S, Stahl-Hennig C. Flow cytometric characterization of the lymphocyte composition in a variety of mucosal tissues in healthy rhesus macaques. J Med Primatol 2010, 40(1):41-51.
23. Schultheiss T. Strong virus-specific mucosal immune responses in SIV-infected rhesus monkeys significantly contribute to viral containment and long-term survival. 2010, http://www.europrise.org/
24. Kaiserlian D. How to break oral tolerance to make an efficient HIV vaccine: lessons from animal model?. 2010, http://www.europrise.org/
25. Berry N, Stebbings R, Ferguson D, Ham C, Alden J, Brown S, Jenkins A, Lines J, Duffy L, Davis L, et al. Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8). J Gen Virol 2008, 89:2240-2251. 10.1099/vir.0.2008/001693-0, 18753233.
26. Arthur LO, Bess JW, Sowder RC, Benveniste RE, Mann DL, Chermann JC, Henderson LE. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 1992, 258:1935-1938. 10.1126/science.1470916, 1470916.
27. Arthur LO, Bess JW, Urban RG, Strominger JL, Morton WR, Mann DL, Henderson LE, Benveniste RE. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol 1995, 69:3117-3124. 189013, 7707540.
28. Wilfingseder D, Spruth M, Ammann CG, Dopper S, Speth C, Dierich MP, Stoiber H. Complement-mediated enhancement of HIV-1 neutralisation by anti-HLA antibodies derived from polytransfused patients. Int Arch Allergy Immunol 2003, 131:62-72. 10.1159/000070437, 12759492.
29. Fenyo EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, et al. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 2009, 4:e4505. 10.1371/journal.pone.0004505, 2640999, 19229336.
30. Nordqvist A, Fenyo EM. Plaque-reduction assays for human and simian immunodeficiency virus neutralization. Methods Mol Biol 2005, 304:273-285.
31. Mainetti L, Mullins J, Scarlatti G. Viral characterization and humoral immune response to HIV in the setting of acute HIV infection. Aids Research and Human Retroviruses 2010, 26.
32. Cavarelli M, Karlsson I, Ripamonti C, Plebani A, Fenyo EM, Scarlatti G. Flexible use of CCR5 in the absence of CXCR4 use explains the immune deficiency in HIV-1 infected children. AIDS 2010, 24:2527-2533. 10.1097/QAD.0b013e32833d7d8c, 20683317.
33. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 2010, 201:1045-1053. 10.1086/651144, 20170371.
34. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009, 83:7337-7348. 10.1128/JVI.00110-09, 2704778, 19439467.
35. van Gils MJ, Bunnik EM, Burger JA, Jacob Y, Schweighardt B, Wrin T, Schuitemaker H. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J Virol 2010, 84:3576-3585. 10.1128/JVI.02622-09, 2838121, 20071586.
36. Bunnik EM, Euler Z, Welkers MR, Boeser-Nunnink BD, Grijsen ML, Prins JM, Schuitemaker H. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat Med 2010, 16:995-997. 10.1038/nm.2203, 20802498.
37. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861. 10.1126/science.1187659, 20616233.
38. Ljunggren K, Moschese V, Broliden PA, Giaquinto C, Quinti I, Fenyo EM, Wahren B, Rossi P, Jondal M. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 1990, 161:198-202. 10.1093/infdis/161.2.198, 2299204.
39. Sawyer LA, Katzenstein DA, Hendry RM, Boone EJ, Vujcic LK, Williams CC, Zeger SL, Saah AJ, Rinaldo CR, Phair JP, et al. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1990, 6:341-356. 10.1089/aid.1990.6.341, 1971182.
40. Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009, 4:388-393. 10.1097/COH.0b013e32832f0a89, 2882066, 20048702.
41. Pensieroso S, Cagigi A, Palma P, Nilsson A, Capponi C, Freda E, Bernardi S, Thorstensson R, Chiodi F, Rossi P. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci USA 2009, 106:7939-7944. 10.1073/pnas.0901702106, 2683072, 19416836.
42. Matucci A, Rossolillo P, Baroni M, Siccardi AG, Beretta A, Zipeto D. HLA-C increases HIV-1 infectivity and is associated with gp120. Retrovirology 2008, 5:68. 10.1186/1742-4690-5-68, 2531131, 18673537.
43. Vicenzi E, Bordignon PP, Biswas P, Brambilla A, Bovolenta C, Cota M, Sinigaglia F, Poli G. Envelope-dependent restriction of human immunodeficiency virus type 1 spreading in CD4(+) T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation. J Virol 1999, 73:7515-7523. 104278, 10438841.
44. Cassani B, Mirolo M, Cattaneo F, Benninghoff U, Hershfield M, Carlucci F, Tabucchi A, Bordignon C, Roncarolo MG, Aiuti A. Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood 2008, 111:4209-4219. 10.1182/blood-2007-05-092429, 2288726, 18218852.
45. Cavarelli M, Foglieni C, Rescigno M, Scarlatti G. Dendritic cells sample HIV-1 through an intestinal epithelial cell monolayer. Retrovirology 2009, 6(Suppl 1).
46. Poli G. Post-entry events of efficient R5 vs. inefficient X4 HIV-1 replication in primary CD4+ T lymphocytes, a transciptome analysis. 2010, http://www.europrise.org/
47. Medaglini D. Primary T cell response to mucosal vaccination. 2010, http://www.europrise.org
48. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC. HIV vaccine research: the way forward. Science 2008, 321:530-532. 10.1126/science.1161000, 18653883.
49. Haigwood NL. Predictive value of primate models for AIDS. AIDS Rev 2004, 6:187-198.